Bioinformatic analysis reveals the key pathways and genes in early-onset breast cancer
- 25 Downloads
Early-onset breast cancer is the most prevalent cancer in the female. To identify the differentially expressed genes and the key signaling pathways in early-onset breast cancer, we have carried out the bioinformatic analysis of an RNA array dataset in the GEO database, GSE109169, which was acquired from early-onset breast cancer patient. A total of 118 differentially expressed genes in early-onset breast cancer were significantly changed compared with that in adjacent normal tissues. Most of these genes are classified into three categories: signaling molecule, enzyme modulator, and hydrolase. Gene ontology terms reveal that most of these genes are involved in cellular and metabolic processes, biological regulation, binding and catalytic activities, and receptor regulation. Protein–protein interaction network was constructed and has two highly enriched modules: one with up-regulated genes and the other with down-regulated genes. The singling pathways are mainly enriched in the cellular immune system, lipid metabolism and other types of metabolic pathways. Finally, we have plotted the Kaplan–Meier curves of two up-regulated and two down-regulated genes for the overall survival prediction in breast cancer. These results greatly expand the current view of early-onset breast cancer and shed light on the discovery of drug candidates and the improvement for the prognosis.
KeywordsEarly-onset breast cancer Bioinformatic analysis Protein–protein interactions Gene ontology and pathway analysis
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflicts of interest.
- 2.Carroll JC, Cremin C, Allanson J, Blaine SM, Dorman H, Gibbons CA, et al. Hereditary breast and ovarian cancers. Can Fam Phys. 2008;54(12):1691–2.Google Scholar
- 9.Nichols KE, Malkin D, Garber JE, Fraumeni JF Jr, Li FP. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomark Prev. 2001;10(2):83–7.Google Scholar
- 14.Masciari S, Dillon DA, Rath M, Robson M, Weitzel JN, Balmana J, et al. Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort. Breast Cancer Res Treat. 2012;133(3):1125–30. https://doi.org/10.1007/s10549-012-1993-9.CrossRefPubMedPubMedCentralGoogle Scholar
- 18.Dite GS, Whittemore AS, Knight JA, John EM, Milne RL, Andrulis IL, et al. Increased cancer risks for relatives of very early-onset breast cancer cases with and without BRCA1 and BRCA2 mutations. Br J Cancer. 2010;103(7):1103–8. https://doi.org/10.1038/sj.bjc.6605876.CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Nilsson MP, Hartman L, Idvall I, Kristoffersson U, Johannsson OT, Loman N. Long-term prognosis of early-onset breast cancer in a population-based cohort with a known BRCA1/2 mutation status. Breast Cancer Res Treat. 2014;144(1):133–42. https://doi.org/10.1007/s10549-014-2842-9.CrossRefPubMedPubMedCentralGoogle Scholar
- 27.Lanczky A, Nagy A, Bottai G, Munkacsy G, Szabo A, Santarpia L, et al. miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients. Breast Cancer Res Treat. 2016;160(3):439–46. https://doi.org/10.1007/s10549-016-4013-7.CrossRefPubMedGoogle Scholar
- 28.Assi HA, Khoury KE, Dbouk H, Khalil LE, Mouhieddine TH, El Saghir NS. Epidemiology and prognosis of breast cancer in young women. J Thorac Dis. 2013;5(Suppl 1):S2–8. https://doi.org/10.3978/j.issn.2072-1439.2013.05.24.PubMedPubMedCentralGoogle Scholar
- 36.Paul D, Ghorai S, Dinesh US, Shetty P, Chattopadhyay S, Santra MK. Cdc20 directs proteasome-mediated degradation of the tumor suppressor SMAR1 in higher grades of cancer through the anaphase promoting complex. Cell Death Dis. 2017;8(6):e2882. https://doi.org/10.1038/cddis.2017.270.CrossRefPubMedPubMedCentralGoogle Scholar